Active Biotech confirms ANYARA tumor PET localization in cancer patients

04-Oct-2005

In an ongoing clinical Phase I study, specific tumor localization of Active Biotech's candidate drug ANYARA, has now been objectively confirmed. Using positron emission tomography (PET) and radioactively labeled ANYARA, drug concentrations in tumor and normal tissues of individual patients have been measured for the first time, demonstrating that ANYARA localizes to tumors that express the target antigen 5T4. The study is ongoing at Paterson Institute for Cancer Research and at Christie Hospital, Manchester, UK.

Another Phase I clinical dose escalation trial with ANYARA is ongoing at the Fox Chase Cancer Center in Philadelphia, USA, at the Norwegian Radium Hospital in Oslo, Norway and at Christie Hospital, Manchester, UK.

Other news from the department research and development

More news from our other portals

So close that even
molecules turn red...